Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The Prescription Drug Price Relief Act of 2025 requires HHS to identify brand-name drugs whose U.S. average manufacturer price exceeds the median price in five reference countries, or is otherwise deemed unreasonable. For drugs determined excessive, the bill voids government-granted exclusivities, issues open non-exclusive licenses to allow generic/biosimilar competition, sets reasonable royalty rules, mandates manufacturer price and cost reporting, creates a public database, and authorizes civil remedies and penalties for noncompliance.
Whether voiding government exclusivities is appropriate versus protecting IP
Relative to its intended legislative type, this bill is a substantive policy change that is detailed in many critical respects (price test, waiver of enumerated exclusivities, open licensing framework, royalty rules, reporting and database requirements, and enforcement mechanisms).
The Prescription Drug Price Relief Act of 2025 requires HHS to identify brand-name drugs whose U.S. average manufacturer price exceeds the median price in five reference countries, or is otherwise deemed unreasonable.
For drugs determined excessive, the bill voids government-granted exclusivities, issues open non-exclusive licenses to allow generic/biosimilar competition, sets reasonable royalty rules, mandates manufacturer price and cost reporting, creates a public database, and authorizes civil remedies and penalties for noncompliance.
Substantive overhaul of exclusivities and compulsory licensing is legally and politically fraught; major opposition and litigation risk reduce prospects.
Relative to its intended legislative type, this bill is a substantive policy change that is detailed in many critical respects (price test, waiver of enumerated exclusivities, open licensing framework, royalty rules, reporting and database requirements, and enforcement mechanisms). It provides clear statutory cross-references and assigns primary responsibility to the Secretary of HHS.
Whether voiding government exclusivities is appropriate versus protecting IP
These are examples from the analysis, not a ranked list of the most-affected groups.
Whether voiding government exclusivities is appropriate versus protecting IP
Likely strongly supportive: the bill directly targets high U.S. drug prices by removing statutory exclusivities and enabling competition.
It aligns with priorities to expand access and lower out-of-pocket costs, while requiring public reporting and rebates to NIH-funded research.
Mixed but cautiously receptive: supports lowering drug costs and improving transparency, yet concerned about legal, administrative, and innovation consequences.
Would seek clearer safeguards, empirical review, and phased implementation to limit unforeseen harms.
Likely strongly opposed: views the bill as major federal overreach that weakens patent and commercial protections, undermines incentives for pharmaceutical innovation, and risks legal conflicts with IP law.
Concerned about administrative takeover of pricing.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Substantive overhaul of exclusivities and compulsory licensing is legally and politically fraught; major opposition and litigation risk reduce prospects.
The bill has not accumulated any surfaced votes yet.
Whether voiding government exclusivities is appropriate versus protecting IP
Substantive overhaul of exclusivities and compulsory licensing is legally and politically fraught; major opposition and litigation risk red…
Relative to its intended legislative type, this bill is a substantive policy change that is detailed in many critical respects (price test, waiver of enumerated exclusivities, open licensing framework, royalty rules, re…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.